Esuprone

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by DePiep (talk | contribs) at 19:14, 16 November 2015 (Chembox unknown parameters: rename, fix sp, or remove. See Template:Chembox/doc/full parameter list (via AWB script)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Esuprone
Names
IUPAC name
3,4-Dimethyl-2-oxo-2H-chromen-7-yl ethanesulfonate
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
UNII
  • InChI=1S/C13H14O5S/c1-4-19(15,16)18-10-5-6-11-8(2)9(3)13(14)17-12(11)7-10/h5-7H,4H2,1-3H3 checkY
    Key: CHDGAVDQRSPBTA-UHFFFAOYSA-N checkY
  • InChI=1/C13H14O5S/c1-4-19(15,16)18-10-5-6-11-8(2)9(3)13(14)17-12(11)7-10/h5-7H,4H2,1-3H3
    Key: CHDGAVDQRSPBTA-UHFFFAOYAR
  • O=S(=O)(Oc2ccc\1c(OC(=O)/C(=C/1C)C)c2)CC
Properties[1]
C13H14O5S
Molar mass 282.31 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

Esuprone is an experimental drug candidate being investigated as an antidepressant.[2] It acts as an monoamine oxidase A (MAO-A) inhibitor.[3]

References

  1. ^ Ganellin, C. R (1996). Dictionary of pharmacological agents. CRC Press. p. 1056. ISBN 978-0-412-46630-4.
  2. ^ Vértes, Attila (2003). Handbook of nuclear chemistry. Springer. p. 155. ISBN 978-1-4020-1316-4.
  3. ^ Bergström, M; Westerberg, G; Németh, G; Traut, M; Gross, G; Greger, G; Müller-Peltzer, H; Safer, A; et al. (1997). "MAO-A inhibition in brain after dosing with esuprone, moclobemide and placebo in healthy volunteers: In vivo studies with positron emission tomography". European journal of clinical pharmacology. 52 (2): 121–8. doi:10.1007/s002280050260. PMID 9174681.